Fly News Breaks for February 14, 2020
Feb 14, 2020 | 08:06 EDT
Oppenheimer analyst Steven Lichtman raised his price target for DexCom to $285 from $250 following the company's Q4 results, with sales ahead of January's pre-announcement and operating margin well ahead of estimates. While competitive dynamics continue to bear watching, Lichtman says near-term tailwinds remain including overall strong CGM market growth, pharmacy channel expansion, recent G6 Medicare launch and solid international expansion.
News For DXCM From the Last 2 Days
There are no results for your query DXCM